文献速递妇产影像儿科影像技术与安全US

产前外显子组测序及其对围产期结局的影响:队列研究

Prenatal exome sequencing and impact on perinatal outcome: cohort study.
PubMed 文献 · Ultrasound Obstet Gynecol · 2023-01-01

英国一家三级胎儿医学中心回顾性队列研究显示,在R21通路下产前外显子组测序诊断率为23.4%(11/47),是否同意测序两组晚期终止妊娠比例无差异(25.0% vs 25.0%,P=1.0),但检出致病变异者晚期终止妊娠比例显著高于无信息结果者(63.6% vs 13.9%,P<0.0009),且检出致病变异者结果周转时间更长。

要点

  • 产前外显子组测序诊断致病性变异率为23.4%(11/47),可影响晚期终止妊娠决策。
  • 检出致病变异者晚期终止妊娠比例63.6%(7/11),显著高于无信息结果者13.9%(5/36)。
  • 检出致病变异者结果周转中位时间22天(IQR 19-34),长于无信息结果者14天(IQR 10-15)。

核心结论

  • 本研究显示产前外显子组测序检出致病变异可能影响晚期终止妊娠决策;随着R21通路持续发展,作者敦促临床医生和政策制定者考虑引入更早的异常筛查、制定晚期终止妊娠的稳健指南并确保为夫妇提供优化支持。

研究设计与样本

  • 回顾性队列研究,纳入2021年3月1日至2022年2月28日转诊至利物浦妇女医院胎儿医学中心的异常胎儿72例;产前外显子组测序作为R21通路的一部分,采用Illumina下一代测序平台进行三人组外显子测序,评估974个产前相关基因和231个专家审查基因的编码区和剪接区;比较人口学、表型、产前外显子组测序结果和围产期结局,使用IBM SPSS version 28.0.1.0进行描述性统计和χ方检验或Fisher精确检验。

诊断标准与关键数值

  • 产前外显子组测序诊断率为23.4%(11/47)。
  • 同意产前外显子组测序组与未提议或未同意组晚期终止妊娠比例分别为25.0%(12/48)和25.0%(6/24),P=1.0。
  • 检出致病变异组与产前外显子组测序无信息组晚期终止妊娠比例分别为63.6%(7/11)和13.9%(5/36),P<0.0009。
  • 检出致病变异组与无信息组结果周转中位时间分别为22天(IQR 19-34天)和14天(IQR 10-15天),P<0.0001。

临床应用与阅片要点

  • 作者敦促临床医生和政策制定者考虑引入更早的异常筛查、制定晚期终止妊娠的稳健指南并确保为夫妇提供优化支持。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: First, to determine the uptake of prenatal exome sequencing (pES) and the diagnostic yield of pathogenic (causative) variants in a UK tertiary fetal medicine unit following the introduction of the NHS England Rapid Exome Sequencing Service for fetal anomalies testing (R21 pathway). Second, to identify how the decision to proceed with pES and identification of a causative variant affect perinatal outcomes, specifically late termination of pregnancy (TOP) at or beyond 22 weeks' gestation.

METHODS: This was a retrospective cohort study of anomalous fetuses referred to the Liverpool Women's Hospital Fetal Medicine Unit between 1 March 2021 and 28 February 2022. pES was performed as part of the R21 pathway. Trio exome sequencing was performed using an Illumina next-generation sequencing platform assessing coding and splice regions of a panel of 974 prenatally relevant genes and 231 expert reviewed genes. Data on demographics, phenotype, pES result and perinatal outcome were extracted and compared. Descriptive statistics and the χ-square or Fisher's exact test were performed using IBM SPSS version 28.0.1.0.

RESULTS: In total, 72 cases were identified and two-thirds of eligible women (n = 48) consented to trio pES. pES was not feasible in one case owing to a low DNA yield and, therefore, was performed in 47 cases. In one-third of cases (n = 24), pES was not proposed or agreed. In 58.3% (14/24) of these cases, this was because invasive testing was declined and, in 41.7% (10/24) of cases, women opted for testing and underwent chromosomal microarray analysis only. The diagnostic yield of pES was 23.4% (11/47). There was no overall difference in the proportion of women who decided to have late TOP in the group in which pES was agreed compared with the group in which pES was not proposed or agreed (25.0% (12/48) vs 25.0% (6/24); P = 1.0). However, the decision to have late TOP was significantly more frequent when a causative variant was detected compared with when pES was uninformative (63.6% (7/11) vs 13.9% (5/36); P < 0.0009). The median turnaround time for results was longer in cases in which a causative variant was identified than in those in which pES was uninformative (22 days (interquartile range (IQR), 19-34) days vs 14 days (IQR, 10-15 days); P < 0.0001).

CONCLUSIONS: This study demonstrates the potential impact of identification of a causative variant by pES on decision to have late TOP. As the R21 pathway continues to evolve, we urge clinicians and policymakers to consider introducing earlier screening for anomalies, developing robust guidance for late TOP and ensuring optimized support for couples. © 2022 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Poljak B, Agarwal U, Alfirevic Z, et al. Prenatal exome sequencing and impact on perinatal outcome: cohort study. Ultrasound Obstet Gynecol. 2023. PMID: 36508432. doi:10.1002/uog.26141

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。